Cargando…
Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden
SIMPLE SUMMARY: Hereditary diffuse gastric cancer (HDGC) is an inherited cancer syndrome associated with CDH1 germline mutations. The increasing detection of CDH1 genetic variants due to multigene panel testing poses a serious clinical challenge and urges the development of effective classification...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430832/ https://www.ncbi.nlm.nih.gov/pubmed/34503169 http://dx.doi.org/10.3390/cancers13174359 |
_version_ | 1783750796682199040 |
---|---|
author | Figueiredo, Joana Mercadillo, Fátima Melo, Soraia Barroso, Alicia Gonçalves, Margarida Díaz-Tasende, José Carneiro, Patrícia Robles, Luis Colina, Francisco Ibarrola, Carolina Perea, José Morais-de-Sá, Eurico Seruca, Raquel Urioste, Miguel |
author_facet | Figueiredo, Joana Mercadillo, Fátima Melo, Soraia Barroso, Alicia Gonçalves, Margarida Díaz-Tasende, José Carneiro, Patrícia Robles, Luis Colina, Francisco Ibarrola, Carolina Perea, José Morais-de-Sá, Eurico Seruca, Raquel Urioste, Miguel |
author_sort | Figueiredo, Joana |
collection | PubMed |
description | SIMPLE SUMMARY: Hereditary diffuse gastric cancer (HDGC) is an inherited cancer syndrome associated with CDH1 germline mutations. The increasing detection of CDH1 genetic variants due to multigene panel testing poses a serious clinical challenge and urges the development of effective classification strategies. In this study, we describe the identification of the novel CDH1 G212E variant in a large family strongly affected by diffuse gastric cancer. Through a comprehensive characterization pipeline, we provide evidence of the damaging nature of this genetic alteration, thus impacting patient management and family screening. ABSTRACT: E-cadherin, encoded by CDH1, is an essential molecule for epithelial homeostasis, whose loss or aberrant expression results in disturbed cell–cell adhesion, increased cell invasion and metastasis. Carriers of CDH1 germline mutations have a high risk of developing diffuse gastric cancer and lobular breast cancer, associated with the cancer syndrome Hereditary Diffuse Gastric Cancer (HDGC). The ubiquitous availability of cancer panels has led to the identification of an increasing amount of “incidental” CDH1 genetic variants that pose a serious clinical challenge. This has sparked intensive research aiming at an accurate classification of the variants and consequent validation of their clinical relevance. The present study addressed the significance of a novel CDH1 variant, G212E, identified in an unusually large pedigree displaying strong aggregation of diffuse gastric cancer. We undertook a comprehensive pipeline encompassing family data, in silico predictions, in vitro assays and in vivo strategies, which validated the deleterious phenotype induced by this genetic alteration. In particular, we demonstrated that the G212E variant affects the stability and localization, as well as the adhesive and anti-invasive functions of E-cadherin, triggering epithelial disruption and disorganization. Our findings illustrate the clinical implication of a complementary approach for effective variant categorization and patient management. |
format | Online Article Text |
id | pubmed-8430832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84308322021-09-11 Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden Figueiredo, Joana Mercadillo, Fátima Melo, Soraia Barroso, Alicia Gonçalves, Margarida Díaz-Tasende, José Carneiro, Patrícia Robles, Luis Colina, Francisco Ibarrola, Carolina Perea, José Morais-de-Sá, Eurico Seruca, Raquel Urioste, Miguel Cancers (Basel) Article SIMPLE SUMMARY: Hereditary diffuse gastric cancer (HDGC) is an inherited cancer syndrome associated with CDH1 germline mutations. The increasing detection of CDH1 genetic variants due to multigene panel testing poses a serious clinical challenge and urges the development of effective classification strategies. In this study, we describe the identification of the novel CDH1 G212E variant in a large family strongly affected by diffuse gastric cancer. Through a comprehensive characterization pipeline, we provide evidence of the damaging nature of this genetic alteration, thus impacting patient management and family screening. ABSTRACT: E-cadherin, encoded by CDH1, is an essential molecule for epithelial homeostasis, whose loss or aberrant expression results in disturbed cell–cell adhesion, increased cell invasion and metastasis. Carriers of CDH1 germline mutations have a high risk of developing diffuse gastric cancer and lobular breast cancer, associated with the cancer syndrome Hereditary Diffuse Gastric Cancer (HDGC). The ubiquitous availability of cancer panels has led to the identification of an increasing amount of “incidental” CDH1 genetic variants that pose a serious clinical challenge. This has sparked intensive research aiming at an accurate classification of the variants and consequent validation of their clinical relevance. The present study addressed the significance of a novel CDH1 variant, G212E, identified in an unusually large pedigree displaying strong aggregation of diffuse gastric cancer. We undertook a comprehensive pipeline encompassing family data, in silico predictions, in vitro assays and in vivo strategies, which validated the deleterious phenotype induced by this genetic alteration. In particular, we demonstrated that the G212E variant affects the stability and localization, as well as the adhesive and anti-invasive functions of E-cadherin, triggering epithelial disruption and disorganization. Our findings illustrate the clinical implication of a complementary approach for effective variant categorization and patient management. MDPI 2021-08-28 /pmc/articles/PMC8430832/ /pubmed/34503169 http://dx.doi.org/10.3390/cancers13174359 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Figueiredo, Joana Mercadillo, Fátima Melo, Soraia Barroso, Alicia Gonçalves, Margarida Díaz-Tasende, José Carneiro, Patrícia Robles, Luis Colina, Francisco Ibarrola, Carolina Perea, José Morais-de-Sá, Eurico Seruca, Raquel Urioste, Miguel Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden |
title | Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden |
title_full | Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden |
title_fullStr | Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden |
title_full_unstemmed | Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden |
title_short | Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden |
title_sort | germline cdh1 g212e missense variant: combining clinical, in vitro and in vivo strategies to unravel disease burden |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430832/ https://www.ncbi.nlm.nih.gov/pubmed/34503169 http://dx.doi.org/10.3390/cancers13174359 |
work_keys_str_mv | AT figueiredojoana germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT mercadillofatima germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT melosoraia germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT barrosoalicia germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT goncalvesmargarida germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT diaztasendejose germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT carneiropatricia germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT roblesluis germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT colinafrancisco germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT ibarrolacarolina germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT pereajose germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT moraisdesaeurico germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT serucaraquel germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden AT uriostemiguel germlinecdh1g212emissensevariantcombiningclinicalinvitroandinvivostrategiestounraveldiseaseburden |